PubMed Health⌕ Search

Biomedical subjects

P Edgar

Publications and source records attributed to P Edgar.

9 recordsLinked to original sources
PubMed1995

The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.

3-hydroxy,3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce biliary cholesterol saturation index (CSI) in duodenal bile in hypercholesterolemic patients and might be useful for gallstone dissolution. However, preliminary data suggest that these drugs are not effective in this respect. We therefore studied 33 patients with radiolucent gallstones in an opacifying gallbladder who were scheduled for elective cholecystectomy. Patients were treated with 40 mg pravastatin day-1 or placebo during the 3 weeks before surgery. Six patients could not be evaluated. Baseline characteristics (age, sex, body mass index, serum cholesterol, and the solitary/multiple gallstone ratio) were similar in both groups. Serum cholesterol fell by 39% in the pravastatin group (P < .001) and remained unchanged in the placebo group. Biliary cholesterol (9.5 +/- 1.3 vs. 14.3 +/- 1.5 mmol/L, P = .026), and phospholipid concentrations (24.8 +/- 3.9 vs. 36.7 +/- 3.9 mmol/L, P = .043) were lower in the pravastatin group. Although bile salt concentrations were lower in the pravastatin group (114 +/- 21 vs. 152 +/- 15 mmol/L), this difference was not significant. CSI was not different between both groups (142 +/- 27% [pravastatin] vs. 113 +/- 6% [placebo], P = NS). Cholesterol crystals were present in fresh bile in 7 of 13 patients in the pravastatin group and in 11 of 14 controls (P = NS). Nucleation time was comparable between the 2 groups (13 +/- 3 vs. 9 +/- 3 days, P = NS). Bile salt species and molecular species of phospholipids determined with high-performance liquid chromatography did not differ either between both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Bile↗
PubMed1993

Time-to-contact judgment in the locomotion of adults and preschool children.

The hypothesis of Lee (1976)--that approach and deceleration toward a surface can be controlled through the rate of change of the optic variable tau--was examined for natural human locomotion. In Experiment 1, 12 adults were asked to perform locomotor tasks that required running at speed and then decelerating so that either the hand or head made a controlled contact with a door. In Experiment 2, 12 preschool children performed a relay-running task that required similar control. In Experiment 3, 12 children and 12 adults ran with a stick as an extension to their arm length and performed the same task. The results supported Lee's hypothesis for the initial phase of approach, but subjects switched to a separate adjustment phase 2 to 3 arm lengths from the target. Children did not adopt an appropriate tau strategy for collision avoidance and appeared unable to modify their approach strategy to allow for a hand-held stick.

Acceleration↗
PubMed1989

Enzyme linked immunosorbent assay for measuring antithrombin III.

A competitive ELISA for the measurement of antithrombin III antigen was developed using a pure preparation of antithrombin. This two step immunoassay requires only one antibody binding step and avoids the binding of anti-antithrombin antibody to the solid phase. Plasma samples measured by this ELISA correlated well with measurements taken with immune electrophoresis measurements (r = 0.933); the ELISA was also shown to be both sensitive and precise.

Antithrombin III↗